SEC fines former Merck exec over insider trading allegations

The Se­cu­ri­ties and Ex­change Com­mis­sion said a for­mer Mer­ck ex­ec­u­tive agreed to pay $82,000 af­ter al­leg­ing he pur­chased shares of a com­pa­ny right be­fore it was ac­quired by the drug­mak­er.

Nir­dosh Jago­ta, a for­mer VP of glob­al reg­u­la­to­ry af­fairs at Mer­ck, bought 500 shares of Pan­dion Ther­a­peu­tics’ stock on Feb. 9, 2021, and 500 ad­di­tion­al shares on Feb. 17, 2021, ac­cord­ing to an SEC or­der an­nounced on Mon­day. The ex­ec­u­tive had been in­volved in the due dili­gence process lead­ing up to the deal since Jan­u­ary of that year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN